
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The changes during biopharmaceutical manufacturing, processing and storage can impact the safety and efficacy of products during clinical use. Controlling such product variability is a challenge to maintaining batch-to-batch consistency.






